Preferred Label : Stage IIIC Cutaneous Melanoma AJCC v7;
NCIt synonyms : Stage IIIC Skin Melanoma AJCC v7;
NCIt related terms : Stage IIIC Cutaneous (Skin) Melanoma;
NCIt definition : Stage IIIC includes: (T1-4b, N1b, M0); (T1-4b, N2b, M0); (T1-4b, N2c, M0); (Any T,
N3, M0). T1-4b: Ulcerated cutaneous melanoma of any thickness. N1b: Cutaneous melanoma
with macrometastasis in one regional lymph node. N2b: Cutaneous melanoma with macrometastases
in 2-3 regional lymph nodes. N2c: Cutaneous melanoma with intralymphatic metastases
(in transit or satellite metastases) without metastatic nodes. N3: Cutaneous melanoma
with 4 or more metastatic nodes, or matted nodes, or in transit met(s)/satellite(s)
with metastatic node(s). M0: No detectable evidence of distant metastases. (from AJCC
7th Ed.);
Neoplastic status : Malignant;
NCI Metathesaurus CUI : CL413977;
Origin ID : C86053;
UMLS CUI : C2828036;
Disease may have findings
Has associated anatomic sites
Semantic type(s)
concept_is_in_subset
disease_excludes_finding
disease_has_abnormal_cell
disease_has_finding
disease_has_normal_cell_origin
disease_has_normal_tissue_origin
disease_has_primary_anatomic_site
disease_is_stage
disease_may_have_molecular_abnormality
http://www.e-cancer.fr/content/download/245366/3384641/version/2/file/FICHE+BUM+MELANOME.pdf
2018
false
false
true
France
French
guidelines for drug use
melanoma
Stage IIIC Cutaneous Melanoma AJCC v7
Stage IV Cutaneous Melanoma AJCC v6 and v7
BRAF V600 Mutation
melanoma
neoplasm metastasis
programmed cell death 1 receptor
pembrolizumab
Ipilimumab
Antineoplastic Agents, Immunological
antineoplastic combined chemotherapy protocols
antineoplastic agents
dabrafenib
proto-oncogene proteins b-raf
cobimetinib
enzyme inhibitors
trametinib
Antineoplastic Agents, Immunological
antineoplastic agents
Drug-Related side effects and adverse reactions
genetic testing
cobimetinib
azetidines
piperidines
antibodies, monoclonal
antibodies, monoclonal, humanized
indoles
sulfonamides
imidazoles
oximes
pyridones
pyrimidinones
Vemurafenib
Nivolumab
---